Progressive Liver Dysfunction Resulted from a High-Fat, High-Fructose Diet in MS-NASH (FATZO) Mice
Xiaoli Wang, Weiwei Ye, Yang Chen, Xiaoyu Zhang, Yixin (Jim) Wang, Yong-Fu Xiao
NAFLD/NASH is recognized as the liver manifestation of metabolic syndrome. With no currently approved NASH therapies, and disease pathogenesis not fully elucidated, valid preclinical models recapitulating human disease are needed to further research.
The MS-NASH mouse (formerly called FATZO) is a polygenic model with an intact leptin pathway used in many dysmetabolism studies. The preclinical mouse model was developed by cross breeding C57BL6/J (C57) with AKR/J.
This poster characterizes the induction of a NAFLD/NASH model in MS-NASH mice through the administration of a high fat/fructose diet (HFFD). The resulting model recapitulates both pathological and dysmetabolic features of NAFLD/NASH.
Download this Poster to Discover:
- That MS-NASH mice develop NAFLD on a high fat/fructose diet, with progressive increases in liver enzymes and serum liver biomarkers
- How MS-NASH mice fed with high fat/fructose diet show the apparent characteristics of obesity, hyperglycemia, and dyslipidemia
- That after 4 months on high fat/fructose diet, histological data demonstrates steatosis, inflammation, ballooning, and early signs of fibrosis in MS-NASH mice